Top Page
Ascendis Pharma
(NASDAQ:ASND)
Ascendis Pharma (ASND) vs. SPDR S&P 500 ETF (SPY)
Ascendis Pharma Business Overview & Revenue Model
Ascendis Pharma Key Performance Indicators (KPIs)
Ascendis Pharma Earnings Call Summary
Ascendis Pharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 646.55M | 363.64M | 266.72M | 51.17M | 7.78M | 6.95M |
| Gross Profit | 561.21M | 319.38M | 222.32M | 39.04M | 4.25M | 6.95M |
| EBITDA | -133.16M | -290.02M | -411.17M | -529.18M | -364.64M | -407.81M |
| Net Income | -232.94M | -378.08M | -481.45M | -583.19M | -383.58M | -418.95M |
Balance Sheet | ||||||
| Total Assets | 1.15B | 1.18B | 825.59M | 1.09B | 1.08B | 979.79M |
| Cash, Cash Equivalents and Short-Term Investments | 539.09M | 559.54M | 399.44M | 735.46M | 682.06M | 718.79M |
| Total Debt | 813.65M | 856.62M | 743.06M | 617.57M | 209.92M | 91.97M |
| Total Liabilities | 1.33B | 1.29B | 971.28M | 826.39M | 201.29M | 141.08M |
| Stockholders Equity | -174.07M | -105.71M | -145.70M | 263.35M | 883.63M | 838.71M |
Cash Flow | ||||||
| Free Cash Flow | -112.15M | -307.62M | -469.80M | -510.19M | -441.88M | -293.10M |
| Operating Cash Flow | -106.68M | -306.20M | -467.36M | -495.70M | -417.65M | -271.55M |
| Investing Cash Flow | -5.48M | 6.88M | 286.47M | 61.73M | -110.58M | -291.20M |
| Financing Cash Flow | 27.90M | 443.93M | 134.29M | 396.77M | 351.39M | 602.65M |
Ascendis Pharma Technical Analysis
Ascendis Pharma Risk Analysis
Ascendis Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | $20.77B | 18.07 | 20.04% | ― | 13.50% | 17.16% | |
78 Outperform | $11.81B | 18.56 | 30.56% | ― | 9.93% | 54.33% | |
76 Outperform | $11.09B | 20.68 | 9.07% | ― | 12.31% | 60.21% | |
59 Neutral | $11.59B | -37.97 | -41.22% | ― | 864.21% | 48.12% | |
54 Neutral | $14.81B | -18.89 | ― | ― | 62.46% | -73.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $12.75B | -50.63 | ― | ― | 103.32% | 47.55% |
Ascendis Pharma Corporate Events
On January 9, 2026, Ascendis Pharma outlined a 2026 business and strategic roadmap highlighting strong commercial uptake of YORVIPATH, which had more than 5,300 unique U.S. patient enrollments and broad international availability by year-end 2025, with further launches planned in at least 10 additional countries by the end of 2026 and continued label-expansion trials. The company noted that SKYTROFA secured its first U.S. label expansion in July 2025 for adult growth hormone deficiency and that a Phase 3 basket trial is underway for additional growth-related indications, while its TransCon CNP program is advancing toward key regulatory decisions in the U.S. and Europe for pediatric achondroplasia and into Phase 3 combination studies with TransCon hGH following positive Phase 2 COACH Trial data reported on January 8, 2026. Ascendis also flagged upcoming 2026 data readouts for its TransCon IL-2 β/γ oncology program, progress of partnered assets with Novo Nordisk in obesity and metabolic disease and with Eyconis in ophthalmology, and regulatory momentum in Greater China and Japan via VISEN Pharmaceuticals and Teijin Limited, including an expected early-2026 approval in China for pediatric growth hormone deficiency and an existing Japanese approval of YORVIPATH in August 2025. In a capital allocation move that may support shareholder value and signal confidence in its outlook, the board authorized a $120 million share repurchase program, giving the company flexibility to buy back stock in the open market or through other permitted methods depending on market conditions and other factors.
The most recent analyst rating on (ASND) stock is a Buy with a $246.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On January 8, 2026, Ascendis Pharma reported positive Week 52 topline data from its Phase 2 COACH trial, the first study to evaluate once-weekly combination therapy with TransCon CNP and TransCon hGH in children aged 2 to 11 years with achondroplasia, showing durable increases in growth velocity, improved body proportionality and arm span, and no new safety concerns compared with the individual monotherapies. The results, which included annualized growth velocities above the 97th percentile of average-stature children and maintenance of bone age in line with chronological age, support Ascendis’s strategy to advance a Phase 3 program in pediatric achondroplasia and could strengthen the company’s position in the rare endocrine and skeletal dysplasia market as TransCon CNP undergoes priority regulatory review in the U.S. and Europe and all enrolled children continue on treatment in the COACH trial.
The most recent analyst rating on (ASND) stock is a Buy with a $242.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On December 30, 2025, Ascendis Pharma A/S reported that a scheduled exercise window for its outstanding warrants exercisable into ordinary shares had closed, resulting in a registered increase of its share capital by a nominal DKK 282,197. This brought the company’s total share capital to a nominal DKK 61,977,408 through the issuance of 282,197 new ordinary shares at an average cash consideration of about USD 63.34 per share, strengthening its equity base. In connection with these changes, Ascendis updated and registered amended articles of association with the Danish Business Authority, underscoring the company’s continued use of equity-based incentives and capital market instruments as part of its financing and corporate governance framework.
The most recent analyst rating on (ASND) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On December 9, 2025, Ascendis Pharma’s board of directors granted 27,820 warrants to certain employees, allowing them to subscribe for ordinary shares at an exercise price of $196.63 per share. This move is part of the company’s strategy to incentivize employees and aligns with its Articles of Association, which were amended to accommodate this grant. The vesting schedule for these warrants includes a 25% vesting after one year and the remainder vesting monthly over the next three years, contingent on continued service. This grant leaves 1,725,233 shares available for future warrants, highlighting Ascendis Pharma’s ongoing commitment to leveraging employee incentives to bolster its market position.
The most recent analyst rating on (ASND) stock is a Buy with a $220.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On November 25, 2025, Ascendis Pharma announced that the FDA has extended the PDUFA target action date for the New Drug Application of TransCon CNP for children with achondroplasia by three months to February 28, 2026. This extension follows the submission of additional information by Ascendis on November 5, 2025, which the FDA deemed a major amendment. The delay may impact Ascendis’ timeline for bringing this treatment to market, potentially affecting its competitive positioning in the biopharmaceutical industry.
The most recent analyst rating on (ASND) stock is a Buy with a $242.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On November 11, 2025, Ascendis Pharma’s board of directors granted 41,220 warrants to select employees, allowing them to subscribe to ordinary shares at an exercise price of $201.16 per share. This move, which includes amending the company’s Articles of Association, signifies a strategic effort to incentivize and retain key personnel, potentially impacting the company’s operational dynamics and stakeholder interests.
The most recent analyst rating on (ASND) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Ascendis Pharma released its unaudited condensed consolidated interim financial statements for the period ending September 30, 2025. The company reported a net loss of EUR 60.989 million for the three months ended September 30, 2025, compared to a net loss of EUR 99.198 million in the same period in 2024. Despite the loss, the company showed an increase in revenue to EUR 213.634 million from EUR 57.833 million in the previous year, indicating a significant growth in sales. This financial update may impact the company’s market positioning by highlighting its revenue growth despite ongoing losses, which could influence investor sentiment and strategic decisions moving forward.
The most recent analyst rating on (ASND) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Ascendis Pharma reported strong financial results for the third quarter of 2025, with total revenue reaching €213.6 million, a significant increase from the previous year. The company achieved an operating profit of €11.0 million, driven by the successful global launch of YORVIPATH and the continued uptake of SKYTROFA. The company is advancing its pipeline with TransCon CNP under FDA priority review for treating achondroplasia in children, with a decision expected by the end of November 2025. Ascendis is also expanding its product labels and conducting trials to support further growth, indicating a positive outlook for future innovation and market expansion.
The most recent analyst rating on (ASND) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On October 22, 2025, Ascendis Pharma announced the commercial availability of SKYTROFA (TransCon hGH) in the United States, expanding its dosing options for adults with growth hormone deficiency. This development marks a significant step in the company’s efforts to enhance its product offerings in the endocrinology market, potentially improving its competitive positioning and providing more options for patients and healthcare providers.
The most recent analyst rating on (ASND) stock is a Buy with a $242.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
On October 14, 2025, Ascendis Pharma’s board of directors granted 31,710 warrants to certain employees, allowing them to subscribe for ordinary shares at an exercise price of $208.71 per share. This move, which amends the company’s Articles of Association, is part of their strategy to incentivize employees and aligns with their broader market objectives. The grant leaves 1,794,273 shares available for future warrant issuance, reflecting the company’s ongoing commitment to employee engagement and retention.
The most recent analyst rating on (ASND) stock is a Buy with a $297.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.